Conclusion & References

ED is a common presentation to outpatient clinics, and as comorbid conditions increase, rates of ED are increasing as well. Educating and empowering pharmacists to appropriately screen and assess individuals with erectile dysfunction can improve patient access to care and improve patient quality of life.


  1. Burnett AL, Nehra A, Breau RH, et al. Erectile Dysfunction: AUA Guideline. J Urol. 2018;200(3):633-641. doi:10.1016/j.juro.2018.05.004.
  2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Washington, DC: American Psychiatric Association; 2013.
  3. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol. 1994;151(1):54-61. doi:10.1016/s0022-5347(17)34871-1.
  4. Johannes CB, Araujo AB, Feldman HA, Derby CA, Kleinman KP, McKinlay JB. Incidence of erectile dysfunction in men 40 to 69 years old: Longitudinal results from the Massachusetts Male Aging Study. J Urol 2000; 163:460–463.
  5. Levine GN, Steinke EE, Bakaeen FG, et al. Sexual activity and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2012;125(8):1058-1072. doi:10.1161/CIR.0b013e3182447787
  6. Hodges LD, Kirby M, Solanki J, O’Donnell J, Brodie DA. The temporal relationship between erectile dysfunction and cardiovascular disease. Int J Clin Pract. 2007;61(12):2019-2025. doi:10.1111/j.1742-1241.2007.01629.x.
  7. Montorsi F, Briganti A, Salonia A, et al. Erectile dysfunction prevalence, time of onset and association with risk factors in 300 consecutive patients with acute chest pain and angiographically documented coronary artery disease. Eur Urol. 2003;44(3):360-365. doi:10.1016/s0302-2838(03)00305-1.
  8. Hypertension Prevalence in the U.S.: Million Hearts®. Centers for Disease Control and Prevention. Published March 22, 2021. Accessed April 4, 2021.
  9. Selvin E, Burnett AL, Platz EA. Prevalence and risk factors for erectile dysfunction in the US. Am J Med. 2007;120(2):151-157. doi:10.1016/j.amjmed.2006.06.010.
  10. Seftel AD, Sun P, Swindle R. The prevalence of hypertension, hyperlipidemia, diabetes mellitus and depression in men with erectile dysfunction. J Urol. 2004;171(6 Pt 1):2341-2345. doi:10.1097/01.ju.0000125198.32936.38.
  11. Rosen RC, Fisher WA, Eardley I, et al. The multinational Men’s Attitudes to Life Events and Sexuality (MALES) study: I. Prevalence of erectile dysfunction and related health concerns in the general population. Curr Med Res Opin. 2004;20(5):607-617. doi:10.1185/030079904125003467.
  12. Manolis A, Doumas M. Sexual dysfunction: the ‘prima ballerina’ of hypertension-related quality-of-life complications. J Hypertens. 2008;26(11):2074-2084. doi:10.1097/HJH.0b013e32830dd0c6.
  13. Tóth PP, Potter D, Ming EE. Prevalence of lipid abnormalities in the United States: the National Health and Nutrition Examination Survey 2003-2006. J Clin Lipidol. 2012;6(4):325-330. doi:10.1016/j.jacl.2012.05.002.
  14. Eaton CB, Liu YL, Mittleman MA, Miner M, Glasser DB, Rimm EB. A retrospective study of the relationship between biomarkers of atherosclerosis and erectile dysfunction in 988 men. Int J Impot Res. 2007;19(2):218-225. doi:10.1038/sj.ijir.3901519 .
  15. Romeo JH, Seftel AD, Madhun ZT, Aron DC. Sexual function in men with diabetes type 2: association with glycemic control. J Urol. 2000;163(3):788-791.
  16. Goldstein I. Male sexual circuitry. Working Group for the Study of Central Mechanisms in Erectile Dysfunction. Sci Am. 2000;283(2):70-75.
  17. Yudkin JS, Stehouwer CD, Emeis JJ, Coppack SW. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol. 1999;19(4):972-978. doi:10.1161/01.atv.19.4.972.
  18. Imamura M, Waseda Y, Marinova GV, et al. Alterations of NOS, arginase, and DDAH protein expression in rabbit cavernous tissue after administration of cigarette smoke extract. Am J Physiol Regul Integr Comp Physiol. 2007;293(5):R2081-R2089. doi:10.1152/ajpregu.00406.2007.
  19. Carani CJ, Zini D, Baldini A. Testosterone and prolactin: behavioural and psychophysiological approaches in men. In: Pharmacology of Sexual Function and Dysfunction: Proceedings of the Esteve. Excerpta Medica; 1995.
  20. Rosen RC. Pharmacological effects on nocturnal penile tumescence (NPT). In: Pharmacology of Sexual Function and Dysfunction: Proceedings of the Esteve. Excerpta Medica; 1995.
  21. Rizk PJ, Kohn TP, Pastuszak AW, Khera M. Testosterone therapy improves erectile function and libido in hypogonadal men. Curr Opin Urol. 2017;27(6):511-515. doi:10.1097/MOU.0000000000000442
  22. Corona G, Rastrelli G, Limoncin E, Sforza A, Jannini EA, Maggi M. Interplay Between Premature Ejaculation and Erectile Dysfunction: A Systematic Review and Meta-Analysis. J Sex Med. 2015;12(12):2291-2300. doi:10.1111/jsm.13041 .
  23. Pourmand G, Alidaee MR, Rasuli S, Maleki A, Mehrsai A. Do cigarette smokers with erectile dysfunction benefit from stopping?: a prospective study. BJU Int. 2004;94(9):1310-1313. doi:10.1111/j.1464-410X.2004.05162.x .
  24. Yuan J, Zhang R, Yang Z, et al. Comparative effectiveness and safety of oral phosphodiesterase type 5 inhibitors for erectile dysfunction: a systematic review and network meta-analysis. Eur Urol. 2013;63(5):902-912. doi:10.1016/j.eururo.2013.01.012 .
  25. Esposito K, Ciotola M, Giugliano F, et al. Mediterranean diet improves erectile function in subjects with the metabolic syndrome. Int J Impot Res. 2006;18(4):405-410. doi:10.1038/sj.ijir.3901447 .
  26. Padma-Nathan H, Hellstrom WJ, Kaiser FE, et al. Treatment of men with erectile dysfunction with transurethral alprostadil. Medicated Urethral System for Erection (MUSE) Study Group. N Engl J Med. 1997;336(1):1-7. doi:10.1056/NEJM199701023360101.
  27. Williams G, Abbou CC, Amar ET, et al. Efficacy and safety of transurethral alprostadil therapy in men with erectile dysfunction. MUSE Study Group. Br J Urol. 1998;81(6):889-894. doi:10.1046/j.1464-410x.1998.00703.x .
  28. Lewis RW, Witherington R. External vacuum therapy for erectile dysfunction: use and results. World J Urol. 1997;15(1):78-82. doi:10.1007/BF01275162.
  29. Khayyamfar F, Forootan SK, Ghasemi H, Miri SR, Farhadi E. Evaluating the efficacy of vacuum constrictive device and causes of its failure in impotent patients. Urol J. 2014;10(4):1072-1078. Published 2014 Jan 4.
  30. Brison D, Seftel A, Sadeghi-Nejad H. The resurgence of the vacuum erection device (VED) for treatment of erectile dysfunction. J Sex Med. 2013;10(4):1124-1135. doi:10.1111/jsm.12046.
  31. Montague DK, Jarow JP, Broderick GA, et al. Chapter 1: The management of erectile dysfunction: an AUA update. J Urol. 2005;174(1):230-239. doi:10.1097/01.ju.0000164463.19239.19.
  32. McMahon CG, Samali R, Johnson H. Efficacy, safety and patient acceptance of sildenafil citrate as treatment for erectile dysfunction. J Urol. 2000;164(4):1192-1196.
  33. Avanafil. Lexi-Drugs. Hudson, OH: Lexicomp, 2015.

    Updated March 23, 2021. Accessed April 4, 2021

  34. Sildenafil. Lexi-Drugs. Hudson, OH: Lexicomp, 2015. Updated March 27, 2021. Accessed April 4, 2021

  35. Vardenafil. Lexi-Drugs. Hudson, OH: Lexicomp, 2015. Updated February 18, 2021. Accessed April 4, 2021

  36. Tadalafil. Lexi-Drugs. Hudson, OH: Lexicomp, 2015. Updated February 18, 2021. Accessed April 4, 2021

Close Bitnami banner